Selective Activation of the Adrenomedullin Receptors in Migraine

Sponsor
Danish Headache Center
Study ID
NCT07451769
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Adrenomedullin
  • Brain Diseases
  • Central Nervous System Diseases
  • Migraine
  • Neuropeptides
  • Pain
  • Peptides
  • Signs and Symptoms

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • Adrenomedullin — DRUG
    Continous intravenous infusion of 20 mL (19.9 pmol/kg/min) adrenomedulin over 20 minutes
  • Placebo — OTHER
    Continous intravenous infusion of 20 mL isotonic saline over 20 minutes

Study Details

Adrenomedullin is a neuropeptide implicated in the pathogenesis of migraine. This study investigates whether its administration, after pre-treatment with erenumab (a CGRP-receptor blocking monoclonal antibody), can trigger migraine attacks in individuals with migraine without aura.

Key Dates

First listed
Mar 5, 2026
Start date
Mar 10, 2026
Status verified
Jan 2026
Primary completion
Mar 10, 2027
Completion
Dec 20, 2032

Study Design

Enrollment
26 participants (estimated)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Adrenomedullin
  • Placebo Comparator: Placebo

Primary Outcome Measure

Incidence of migraine attacks [ Time Frame: Assessed from baseline to 12 hours post-infusion of adrenomedullin or placebo ]

Central Contacts

Find similar trials

Nationwide
Migraine trialsNeurology trials

Related Studies